



## The Development and Severity of Infectious Uveitis

Guest Editors:

### **Dr. Ann Marie Lobo**

Department of Ophthalmology,  
University of Illinois College of  
Medicine, Chicago, IL 60612, USA

### **Dr. Pooja Bhat**

Department of Ophthalmology,  
University of Illinois College of  
Medicine, Chicago, IL 60612, USA

### **Dr. Tejabhiram Yadavalli**

Ocular Virology Lab, Department  
of Ophthalmology and Visual  
Sciences, University of Illinois at  
Chicago, Chicago, IL 60612, USA

Deadline for manuscript  
submissions:

**closed (31 January 2022)**

### Message from the Guest Editors

Infections are a leading cause of ocular inflammation worldwide. By exogenous or endogenous transmission, a wide variety of pathogens including bacteria, viruses, fungi, and parasites can cause infectious uveitis. While certain entities such as toxoplasmosis, syphilis, and tuberculosis comprise the majority of cases of intraocular inflammation, other emerging pathogens have also been shown to cause uveitis. The development of infectious uveitis can range from rapidly progressive fulminant infection to a chronic, indolent course. Diagnosis of intraocular infections can be challenging and multiple factors may lead to significant ocular morbidity including delay in diagnosis, drug-resistant infections, and concomitant inflammation, which can destroy ocular tissues. This Special Issue seeks manuscripts on the pathogenesis, severity, diagnosis, and management of infectious uveitis with a special focus on clinical presentation and management challenges, new diagnostic testing modalities, and antimicrobial drug delivery options.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)